Detalles de la búsqueda
1.
The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
Am J Physiol Endocrinol Metab
; 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38864815
2.
Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats.
Am J Physiol Endocrinol Metab
; 325(5): E529-E539, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792041
3.
The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
J Pharmacol Exp Ther
; 384(3): 406-416, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36418115
4.
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.
Br J Pharmacol
; 181(12): 1829-1842, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38378168
5.
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Eur J Pharmacol
; 962: 176215, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38056618
Resultados
1 -
5
de 5
1
Próxima >
>>